TRAIL-expressing cell membrane nanovesicles as an anti-inflammatory platform for rheumatoid arthritis therapy
- 10 April 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 320, 304-313
- https://doi.org/10.1016/j.jconrel.2020.01.054
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (U1705281, 81925019, 81422023, 81871404, 81860386, 81603015)
- National Key Research and Development Program of China (2017YFA0205201, 2018YFC1105900)
- Fundamental Research Funds for the Central Universities (20720190088)
- Program for New Century Excellent Talents in University (NCET-13-0502)
This publication has 45 references indexed in Scilit:
- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2014
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnnals Of The Rheumatic Diseases, 2013
- The Pathogenesis of Rheumatoid ArthritisThe New England Journal of Medicine, 2011
- Treatment of arthritis by macrophage depletion and immunomodulation: Testing an apoptosis‐mediated therapy in a humanized death receptor mouse modelArthritis & Rheumatism, 2011
- New therapies for treatment of rheumatoid arthritisThe Lancet, 2007
- Molecular mechanisms of cell recruitment to inflammatory sites: general and tissue-specific pathwaysRheumatology, 2005
- Effects of disease‐modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor κB, osteoprotegerin, and receptor activator of nuclear factor κB ligandArthritis & Rheumatism, 2004
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisThe New England Journal of Medicine, 2004
- Osteoclasts are essential for TNF-α–mediated joint destructionJCI Insight, 2002
- Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twinsArthritis & Rheumatism, 2000